To the full analysis
Buyback calculator for Viridian Therapeutics
Viridian Therapeutics stock: key metrics
VRDNViridian Therapeutics had an operating margin of −512.9% and a return on invested capital (ROIC) of −37.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | 31.0% | −91.4% | −163.7% |
| 2013 | 42.1% | −4.5% | −50.0% |
| 2014 | 24.9% | −159.0% | −182.6% |
| 2015 | 2.6% | −440.8% | −446.3% |
| 2016 | 23.6% | −374.8% | −379.8% |
| 2017 | −390.2% | −662.8% | −662.3% |
| 2018 | −262.8% | −394.5% | −390.0% |
| 2019 | 100.0% | −941.0% | −938.6% |
| 2020 | −2,595.6% | −10,512.4% | −10,544.3% |
| 2021 | 100.0% | −2,690.8% | −2,680.2% |
| 2022 | 100.0% | −7,579.2% | −7,329.2% |
| 2023 | 100.0% | −81,035.0% | −75,711.5% |
| 2024 | 100.0% | −99,018.2% | −89,387.1% |
| 2025 | 100.0% | −512.9% | −483.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | 33.6% | no data | −100.0% |
| 2013 | −100.0% | −8.6% | −58.8% |
| 2014 | −100.0% | no data | −97.5% |
| 2015 | −100.0% | −99.8% | −87.8% |
| 2016 | 200.0% | no data | −100.0% |
| 2017 | −68.8% | −86.9% | −50.5% |
| 2018 | −63.7% | −47.4% | −49.4% |
| 2019 | −100.0% | −77.3% | −100.0% |
| 2020 | −92.2% | no data | −84.4% |
| 2021 | −42.3% | −40.6% | −39.0% |
| 2022 | −32.9% | −35.9% | −29.8% |
| 2023 | −53.8% | −46.4% | −48.5% |
| 2024 | −40.2% | −40.8% | −36.4% |
| 2025 | −47.4% | −37.7% | −38.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.